One Drop

Cover Block

PUBLIC

Field	Value
Name	One Drop
Tagline	A diabetes management platform that helps people navigate diabetes together
Headquarters	New York, NY
Founded	2014
Business Model	B2C
Industry	Healthtech (digital diabetes management)
Technology Type	AI / Machine Learning, mobile health
Geography	North America
Founder	Jeff Dachis
Funding Label	Series A (total disclosed approximately $8,000,000)
Lead Strategic Investor	Bayer

Links

PUBLIC

• LinkedIn: https://www.linkedin.com/company/onedroptoday
• Crunchbase: https://www.crunchbase.com/organization/onedrop
• PitchBook: https://pitchbook.com/profiles/company/112129-48
• CB Insights: https://www.cbinsights.com/company/informed-data-systems

Executive Summary

PUBLIC

One Drop is a New York-based digital health company that has spent roughly a decade building a consumer-facing diabetes management platform combining device-agnostic glucose tracking with AI-driven coaching [Crunchbase] [CBInsights]. The company was founded in 2014 by Jeff Dachis, the Razorfish co-founder who turned to digital health after his own Type 1 diabetes diagnosis, and it operates through the legal entity Informed Data Systems [CBInsights] [PitchBook]. Its product ingests data from blood glucose meters, continuous glucose monitors, and insulin pumps, then layers personalized coaching and predictive insights on top, positioning the company in the precision-health subset of digital chronic care [LinkedIn] [CBInsights]. The most consequential commercial development on the public record is a multi-stage relationship with Bayer that began as a licensing arrangement, expanded into a Series B investment, and ultimately produced a co-developed AI platform aimed at cardiovascular disease prevention beyond diabetes alone [pharmaphorum] [Fierce Pharma]. Disclosed primary funding is modest at roughly $8 million in a 2015 Series A, with a subsequent $40 million round referenced in secondary sources whose lead remains unconfirmed [Crunchbase]. The company was named a top-three digital diabetes care provider worldwide in industry rankings cited in 2018 [PRNewswire, 2018], and has experimented with direct-to-consumer television advertising as a customer acquisition channel [Fierce Pharma]. Over the next 12 to 18 months, the items worth tracking are the depth of the Bayer relationship beyond cardiovascular co-development, any expansion into employer or payer channels that would shift the model from pure B2C, and renewed disclosure of subscriber metrics now that several years have passed since the last public traction figures.

Data Accuracy: GREEN -- Confirmed by Crunchbase, CBInsights, LinkedIn, and pharmaphorum.

Taxonomy Snapshot

Axis	Value
Business Model	B2C with strategic pharma licensing
Industry / Vertical	Healthtech, digital chronic disease management
Technology Type	AI / Machine Learning, mobile, connected devices
Geography	North America (HQ New York, NY)
Founding Team	Solo founder, Jeff Dachis (prior Razorfish)
Funding	Series A disclosed $8M; later round referenced at $40M

Company Overview

PUBLIC

One Drop was founded in 2014 by Jeff Dachis, who built the company under the legal entity Informed Data Systems following his own Type 1 diabetes diagnosis [PitchBook] [pharmaphorum]. The founding premise, as Dachis has described in interviews, was that diabetes management was fragmented across hardware, pharmacy, and clinic, and that a software layer combining tracking, coaching, and behavioral nudging could meaningfully improve outcomes for people managing the disease day to day [New Atlas] [pharmaphorum]. The company is headquartered in New York and remains separate from the similarly named One Drop Foundation, the Cirque du Soleil-affiliated water charity, a distinction worth flagging because the two entities frequently appear together in search results [Crunchbase].

The public milestone record begins with a Series A round of roughly $8 million dated June 4, 2015 [Crunchbase]. From there, the most substantive disclosed development is a phased partnership with Bayer: an initial licensing deal granting Bayer access to One Drop's data science, predictive capabilities, and mobile platform, followed by a Series B investment that broadened the licensing to areas outside diabetes, and ultimately a co-developed AI-powered platform aimed at cardiovascular disease prevention [pharmaphorum]. In 2018 the company was recognized in industry rankings as a top-three digital diabetes care provider worldwide [PRNewswire, 2018], and it later moved into mass-media customer acquisition with a television advertising experiment covered by trade press [Fierce Pharma].

Data Accuracy: GREEN -- Confirmed by Crunchbase, PitchBook, pharmaphorum, and PRNewswire.

Product and Technology

MIXED

The core product is a mobile-first diabetes management application that aggregates data from third-party devices and pairs it with software-driven coaching. According to CB Insights, the platform allows users to track glucose levels using blood glucose meters, continuous glucose monitors, and insulin pumps [PUBLIC] [CBInsights], and the mobile application offers personalized coaching covering the interactions between food, insulin, exercise, and glucose readings [PUBLIC] [CBInsights] [ZoomInfo]. One Drop's own LinkedIn description frames the offering as "a precision health company combining continuous diagnostics, predictive analytics and machine learning" in a single digital solution [PUBLIC] [LinkedIn]. The company has historically also sold a connected blood glucose meter and test-strip subscription, which is consistent with the device-plus-software pattern common in connected chronic-care companies, though current SKU-level product configuration is not detailed in the captured public sources.

The more differentiated piece of the technology stack is the predictive analytics layer that Bayer chose to license. The first agreement gave Bayer use of One Drop's data science and mobile platform [PUBLIC] [pharmaphorum]; the expanded agreement, attached to a Series B investment, broadened that license outside diabetes [PUBLIC] [pharmaphorum]; and the most recent disclosed step is a co-developed AI platform targeting cardiovascular disease prevention [PUBLIC] [pharmaphorum]. That progression is meaningful because it implies Bayer was willing to underwrite the predictive engine as a horizontal asset rather than a diabetes-specific feature, which is a stronger validation of the underlying ML work than a single licensing fee would be.

What is not in the public record, and what an investor would want before underwriting product depth, is the size and longitudinal quality of the training dataset, the regulatory posture of the predictive features (whether any are positioned as Software as a Medical Device under FDA frameworks), and the current device-integration roadmap given the rapid evolution of CGM hardware from Dexcom and Abbott. The captured sources do not address these directly.

Data Accuracy: YELLOW -- Product claims confirmed by CBInsights and LinkedIn; the Bayer technology arc is corroborated by pharmaphorum, but current product configuration and dataset scale are not in the public record.

Market Research and Opportunity

PUBLIC

The market backdrop matters because diabetes is one of the few chronic conditions where digital tools, connected hardware, pharmacy, and payer reimbursement are all converging at the same time. Diabetes affects a very large global population and consumes a disproportionate share of healthcare spending, and digital management tools sit at the intersection of consumer health apps, connected medical devices, and employer-sponsored chronic care benefits. The captured sources do not include named third-party TAM figures specific to digital diabetes management, so a sized table is omitted in favor of qualitative framing drawn from the cited research.

Demand drivers visible in the cited record fall into three categories. First, pharma-led interest in software as both a distribution channel and a data asset, evidenced concretely by Bayer's escalating commitments to One Drop from licensing to equity to co-development [pharmaphorum]. Second, the maturation of consumer-grade continuous glucose monitoring, which expands the addressable user base from insulin-dependent patients to a broader prediabetic and metabolic-health audience and which One Drop's device-agnostic architecture is positioned to ingest [CBInsights]. Third, the willingness of digital diabetes companies to invest in mass-market consumer acquisition, a shift signalled by One Drop's move into television advertising [Fierce Pharma].

Adjacent and substitute markets create both pull and pressure. Cardiovascular disease prevention, the explicit target of the co-developed Bayer platform [pharmaphorum], is an adjacency that sits naturally next to diabetes given shared metabolic risk factors, and it expands the relevance of One Drop's data science beyond a single condition. On the substitute side, employer-channel competitors such as Omada Health and payer-integrated programs from Onduo and DarioHealth compete for the same end-user attention, while pure-play CGM hardware vendors increasingly bundle their own software experience.

Regulatory and macro forces to monitor include FDA posture on AI-driven clinical decision support, evolving CMS coverage for continuous glucose monitors in non-insulin-dependent populations, and the broader employer benefits cycle, which has historically rewarded chronic-care vendors with measurable A1C outcomes. The captured public sources do not include One Drop-specific clinical outcomes data; that gap is one of the more material items for an investor to source directly.

Data Accuracy: YELLOW -- Qualitative drivers are sourced to pharmaphorum, Fierce Pharma, and CBInsights; no third-party sized TAM appears in the captured record for this specific subsegment.

Competitive Landscape

MIXED

One Drop sits in a crowded but stratified market where the competitive boundaries between software, devices, coaching, and pharma distribution are actively being redrawn.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
One Drop	Device-agnostic diabetes management app with AI coaching, B2C with pharma licensing	Series A disclosed $8M; later round referenced	Bayer co-development extending predictive engine beyond diabetes	[PUBLIC] [Crunchbase] [pharmaphorum]
Omada Health	Employer-channel digital chronic care across diabetes, hypertension, MSK	Late-stage private	Deep employer and payer distribution	[PUBLIC] [CBInsights]
DarioHealth	Consumer device plus app for diabetes and broader cardiometabolic	Public (Nasdaq: DRIO)	Multi-condition platform with B2B2C pivot	[PUBLIC] [CBInsights]
Glooko	Data aggregation across diabetes devices for clinics and pharma	Late-stage private	Clinic-side workflow and device interoperability	[PUBLIC] [CBInsights]
Dexcom	Continuous glucose monitor hardware with companion software	Public (Nasdaq: DXCM)	Dominant CGM hardware franchise	[PUBLIC] [CBInsights]
MySugr (Roche)	Diabetes logbook and coaching app, integrated with Roche meters	Subsidiary of Roche	Pharma parent distribution	[PUBLIC] [CBInsights]

The table understates how segmented the field actually is. Dexcom, Medtronic, Tandem, and Senseonics are primarily hardware franchises whose software experience exists to retain users on their devices; they are substitutes for One Drop's tracking layer but rarely compete on coaching or behavioral analytics. Omada and Onduo (the Verily and Sanofi joint venture) compete most directly on outcomes and have built their distribution through self-insured employers and health plans rather than the App Store. DarioHealth and MySugr are the most direct B2C analogs, with DarioHealth having moved aggressively into B2B2C and MySugr operating with the distribution advantage of Roche ownership. Glooko sits adjacent as a data aggregation layer, often complementary rather than directly competitive.

Where One Drop has a defensible edge today is the Bayer relationship, which is unusual in its depth: a licensing deal followed by an equity investment followed by a co-developed cardiovascular AI platform is a more layered commitment than most digital health companies secure with a pharma partner [pharmaphorum]. That edge is durable to the extent that the underlying predictive engine continues to outperform pharma-internal alternatives, and perishable to the extent that Bayer could in principle build or acquire a substitute. The device-agnostic architecture is a second source of edge because it allows the app to ride whichever CGM franchise wins the next hardware cycle, rather than betting on one.

Where One Drop is most exposed is the employer and payer channel, which Omada in particular has spent a decade building and which is difficult to enter without a dedicated enterprise sales motion. Pure-B2C economics in chronic care have proven challenging across the category, and the cited move into television advertising suggests acquisition cost pressure rather than viral organic growth [Fierce Pharma]. A second exposure is the hardware bundling risk: if Dexcom or Abbott materially improves the in-house software experience that ships with their CGMs, the value of a third-party app layer compresses.

The most plausible 18-month competitive scenario is bifurcation. Winner if Bayer expands the co-developed platform into a multi-condition, multi-geography commercial product, in which case One Drop becomes the embedded predictive engine for one of the largest pharma franchises in cardiometabolic health. Loser if pure-B2C subscriber economics continue to compress against employer-channel competitors and CGM-bundled software, in which case One Drop's strategic value collapses back into whatever the Bayer relationship alone is worth.

Data Accuracy: YELLOW -- Competitor identities confirmed by CBInsights; positioning is analyst characterization based on the cited public record.

Opportunity

PUBLIC

The size of the prize, if One Drop executes on the Bayer arc and extends it, is materially larger than a standalone diabetes app would suggest.

The headline opportunity is for One Drop to become the embedded software and predictive analytics layer that one or more major pharma companies use to operate digital chronic care at scale across cardiometabolic conditions. The cited evidence makes that outcome reachable rather than purely aspirational because Bayer has already moved through the three steps that typically precede a deeper strategic outcome: a licensing agreement, an equity investment alongside expanded licensing outside diabetes, and a co-developed AI platform targeting cardiovascular disease prevention [pharmaphorum]. Each step represents an escalation of commercial integration that would be unusual to undertake without a working underlying product.

Two or three growth scenarios, each named:

| Scenario | What happens | Catalyst | Why it's plausible | |---|---|---|---|| | Become Bayer's cardiometabolic software stack | The co-developed cardiovascular platform expands into a multi-condition commercial product distributed through Bayer's pharma channels | Commercial launch and uptake of the co-developed CV platform | Bayer has already invested equity and licensed the engine outside diabetes [pharmaphorum] | | Multi-pharma predictive engine | A second pharma licenses the predictive layer for a different therapeutic area, validating the engine as horizontal infrastructure | A second named pharma deal disclosed publicly | The cross-condition licensing structure with Bayer is a template that other pharmas in cardiometabolic, oncology, or respiratory could replicate [pharmaphorum] | | Direct-to-consumer cardiometabolic platform | One Drop expands beyond diabetes into a broader consumer cardiometabolic subscription, marketed alongside CGM hardware penetration | Continued mass-media acquisition combined with CGM availability for non-insulin-dependent users | One Drop has already begun TV-led acquisition [Fierce Pharma] and the platform is device-agnostic across CGMs [CBInsights] |

What compounding looks like in this business is data. Every additional user contributing glucose, behavior, and outcome data improves the predictive accuracy of the coaching engine, which in turn improves outcomes, which in turn strengthens the case to pharma partners that the engine is worth licensing for adjacent conditions. The Bayer arc is itself early evidence that this flywheel is starting to spin: the second and third steps of the partnership were predicated on the first step working well enough to underwrite an equity check and a co-development commitment [pharmaphorum]. A second compounding loop is device coverage; because the platform ingests data from any major glucose meter, CGM, or insulin pump [CBInsights], every new device generation expands the addressable user base without requiring One Drop to win a hardware war it cannot fund.

The size of the win can be framed against publicly traded peers in adjacent positioning. DarioHealth and Dexcom both trade as public benchmarks for, respectively, B2B2C cardiometabolic software and CGM-hardware-plus-software, and the broader category includes acquisitions of digital chronic care companies into pharma and payer parents at meaningful multiples. If the Bayer-embedded scenario plays out, the comparable is closer to a strategic infrastructure asset than to a consumer app, and the realized outcome would more likely be a strategic transaction than a standalone IPO (scenario, not a forecast). If the multi-pharma scenario plays out, the relevant comparable shifts toward independent platform companies that license predictive engines into multiple regulated industries.

Data Accuracy: YELLOW -- Scenario plausibility is anchored to the documented Bayer partnership progression in pharmaphorum and the device-agnostic architecture in CBInsights; outcome sizing is explicitly framed as scenario rather than forecast.

Sources

PUBLIC

1. [Crunchbase] OneDrop - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/onedrop

2. [Crunchbase] Series A - OneDrop - 2015-06-04 | https://www.crunchbase.com/funding_round/onedrop-series-a--14714ac5

3. [Crunchbase] OneDrop - Funding, Financials, Valuation & Investors | https://www.crunchbase.com/organization/onedrop/company_financials

4. [Crunchbase] OneDrop - News & Analysis | https://www.crunchbase.com/organization/onedrop/news_and_analysis

5. [Crunchbase] OneDrop - Recent News & Activity | https://www.crunchbase.com/organization/onedrop/company_overview/overview_timeline

6. [PitchBook] One Drop 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/112129-48

7. [LinkedIn] One Drop company page | https://www.linkedin.com/company/onedroptoday

8. [CBInsights] One Drop - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/informed-data-systems

9. [ZoomInfo] One Drop - Overview, News & Similar companies | https://www.zoominfo.com/c/one-drop/433793893

10. [Mashable] One Drop is revolutionizing diabetes care through an app | https://mashable.com/article/one-drop-diabetes-app

11. [pharmaphorum] Is One Drop the start of a revolution in diabetes management? | https://pharmaphorum.com/news/one-drop-gets-approval-monthly-diabetes-management-solution

12. [pharmaphorum] Digital Health Innovation: All diabetics, unite, one drop at a time | https://deep-dive.pharmaphorum.com/magazine/digital-health-innovation/one-drop-jeff-dachis/

13. [New Atlas] One Drop: The data-driven approach to managing diabetes | https://newatlas.com/one-drop-diabetes-interview/50885/

14. [Fierce Pharma] One Drop begins TV advertising, experimenting with media mix to connect to people with diabetes | https://www.fiercepharma.com/marketing/one-drop-begins-tv-advertising-experimenting-media-mix-to-connect-to-people-diabetes

15. [PRNewswire, 2018] One Drop Recognized As Top-3 Digital Diabetes Care Provider Worldwide | https://www.prnewswire.com/news-releases/one-drop-recognized-as-top-3-digital-diabetes-care-provider-worldwide-300731683.html